Compugen: COM701 Data On Track And Continued Bispecific Rilvegostomig Development

Compugen Ltd. maintains a "Buy" rating, driven by advancing clinical programs and strong partnership with AstraZeneca for rilvegostomig. The company's lead asset, COM701, is on track for phase 1/2 MAIA-ovarian trial results in Q1 2027, targeting a major unmet need in relapsed PSOC. The AstraZeneca partnership, leveraging CGEN's COM902 TIGIT component in rilvegostomig, underpins 12 ongoing phase 3 trials across multiple solid tumors with key data in 2027.